Physician profile
Emily Steenberg
NPI 1558674242
$1,660.36
in general payments reported to CMS, 2019-2025
25 companies · $1,393 in 2025
The $1,393 reported for 2025 was more than what 98% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $89.27 · 2023: $119 · 2024: $59.21 · 2025: $1,393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,571.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,571.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $273.55 | 2025 | Myfembree, Gemtesa |
| Mayne Pharma Commercial LLC | $220.77 | 2025 | |
| Amgen INC. | $201.39 | 2023-2025 | Evenity, Prolia, Repatha |
| Radius Health, INC. | $105.77 | 2025 | Tymlos |
| Axsome Therapeutics, INC. | $81.63 | 2025 | Symbravo, Auvelity |
| Astellas Pharma US INC | $77.96 | 2025 | Veozah |
| Abbvie INC. | $75.40 | 2025 | |
| Merck Sharp & Dohme LLC | $65.91 | 2022-2023 | Vaxneuvance, Gardasil 9 |
| Millicent US INC | $63.96 | 2025 | Femlyv, Intrarosa |
| Exact Sciences Corporation | $59.44 | 2023-2025 | Cologuard Collection Kit |
| Amneal Pharmaceuticals LLC | $58.03 | 2025 | Unithroid |
| Almatica Pharma LLC | $54.10 | 2025 | Teriparatide, Loreev Xr |
| Novo Nordisk INC | $47.46 | 2022-2025 | Wegovy |
| Exeltis, USA INC. | $39.13 | 2025 | Slynd |
| Sanofi Pasteur INC. | $29.96 | 2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $28.60 | 2025 | Voquezna |
| Gilead Sciences, INC. | $26.18 | 2023 | |
| Hologic Sales and Service, LLC | $24.62 | 2024 | Aptima |
| Takeda Pharmaceuticals U.S.A., INC. | $24.08 | 2025 | Trintellix |
| Idorsia Pharmaceuticals US INC | $22.41 | 2025 | Quviviq |
| Pfizer INC. | $17.42 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.49 | 2025 | |
| Lilly USA, LLC | $15.66 | 2025 | Mounjaro |
| Glaxosmithkline, LLC. | $15.25 | 2022 | |
| Dexcom, INC. | $15.19 | 2024 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Steenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.